Cargando…

Effectiveness of a reduced dose of efavirenz plus 2 NRTIs as maintenance antiretroviral therapy with the guidance of therapeutic drug monitoring

INTRODUCTION: Wide inter-patient variation of plasma efavirenz (EFV) concentrations has been observed, and a substantial proportion of HIV-positive patients may have unnecessarily higher plasma EFV concentrations than recommended while receiving EFV-containing combination antiretroviral therapy (cAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shang-Ping, Liu, Wen-Chun, Lee, Kuan-Yeh, Wu, Bing-Ru, Su, Yi-Ching, Wu, Pei-Ying, Zhang, Jun-Yu, Luo, Yu-Zhen, Sun, Hsin-Yun, Chang, Sui-Yuan, Lin, Shu-Wen, Hung, Chien-Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Oral Presentation – Abstract O422
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224938/ https://www.ncbi.nlm.nih.gov/pubmed/25394033 http://dx.doi.org/10.7448/IAS.17.4.19524

Ejemplares similares

Performance des D-dimères pour la classification de la gravité de la COVID-19 dans deux hôpitaux de référence de prise en charge au Cameroun
por: Poka-Mayap, V., et al.
Publicado: (2023)

The clinical development of NRTIs — cautionary tales
por: Cooper, D
Publicado: (2010)

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant
por: Scarsi, Kimberly, et al.
Publicado: (2014)

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
por: Huang, Sung-Hsi, et al.
Publicado: (2017)

Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Efavirenz-Containing Antiretroviral Therapy with or without Rifampicin-Based Anti-Tuberculous Therapy
por: Lee, Kuan-Yeh, et al.
Publicado: (2014)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study
por: Smith, Colette, et al.
Publicado: (2014)

Clinical pharmacokinetics of antiretroviral drugs in Ugandan patients
por: Lamorde, M
Publicado: (2012)

La Bauhaus : crisol de la modernidad
por: Hochman, Elaine S.
Publicado: (2002)

The Bauhaus /
por: Ehrlich, Doreen
Publicado: (1991)

Evolution of resistance in paediatric patients with failure on antiretroviral therapy
por: Orrell, C, et al.
Publicado: (2012)

Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study
por: Carey, Dianne
Publicado: (2014)

Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
por: Clumeck, N, et al.
Publicado: (2010)

Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study
por: May, M, et al.
Publicado: (2012)

First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial
por: Clumeck, Nathan, et al.
Publicado: (2014)

In Vitro and Ex Vivo Inhibition of Human Telomerase by Anti-HIV Nucleoside Reverse Transcriptase Inhibitors (NRTIs) but Not by Non-NRTIs
por: Hukezalie, Kyle R., et al.
Publicado: (2012)

Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014–2018
por: Hill, Andrew, et al.
Publicado: (2014)

Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection
por: Thornhill, John, et al.
Publicado: (2014)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis
por: Lalezari, Jacob, et al.
Publicado: (2014)

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis
por: Brinson, Cynthia, et al.
Publicado: (2014)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

La Bauhaus
Publicado: (1971)

626. The Efficacy and Safety of Maintenance with Doravirine Plus Two NRTIs after Initial Suppression in Adults with HIV-1 in the DRIVE-FORWARD Clinical Trial: Results from the Study Extension through 192 Weeks
por: Cahn, Pedro, et al.
Publicado: (2021)

When to start: as soon as possible
por: Saag, M
Publicado: (2012)

When to start: not so fast
por: Lundgren, J
Publicado: (2012)

Late presenters: what can we do?
por: Mussini, C
Publicado: (2012)

TB and HIV: how can we reduce mortality?
por: Lawn, S
Publicado: (2012)

HIV drug resistance surveillance in low- and middle-income countries: 2004 to 2010
por: Bertagnolio, S, et al.
Publicado: (2012)

Treatment optimization in low- and middle-income countries
por: Cooper, D
Publicado: (2012)

HIV, co-morbidity and ageing
por: Reiss, P
Publicado: (2012)

Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3
por: Nichols, G, et al.
Publicado: (2012)

Does early initiation of ART in infants affect virological and resistance outcomes? Data from the CHER trial after 6 years of follow-up
por: Violari, A, et al.
Publicado: (2012)

Eliminating paediatric infections and keeping mothers alive
por: Gray, G
Publicado: (2012)

Review of life expectancy in people with HIV in settings with optimal ART access: what we know and what we don't
por: Sabin, C
Publicado: (2012)

HIV in women
por: Mulcahy, F
Publicado: (2012)

Currently available medications may not be sufficient for lifelong treatment of HIV
por: Jansson, J, et al.
Publicado: (2012)

HAART rollout in the new fiscal and economic environment
por: Moatti, J
Publicado: (2012)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
por: Maartens, Gary
Publicado: (2020)

Het laatste woord
por: van Venrooij, Marleen
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j93hd3tdsn3ga44f4pbmoqf05b